Pharma's reputation falls in the public eye for the first time since 2018 as the pandemic-era halo slips. However, it remains high despite the slip.
Regulators in Brazil are struggling with gene therapy approvals in the US because now people in Brazil can sue for access and they don't have a big enough budget.
U.S. Senators float proposal to create a voluntary Medicare program that would create incentive payments to combat current drug shortages.
AstraZeneca's Imfinzi holds its spot as the leader in the unresectable non-small cell lung cancer space after Bristol Myers' trial failure.
Merck's Keytruda + chemo combo failed to meet primary endpoints in newly diagnosed endometrial cancer trial.
Merck's Keytruda has a new competitor in ImmunityBio's Ankitva which treats bladder cancer, the issue is Ankitva is used in combination with BCG which is currently in shortage.
AbbVie's Skyrizi and Rinvoq sales are booming, making up for Humira's sales slide after biosimilars are released.
AbbVie's Rinvoq beats Regeneron and Sanofi's Dupixent in a head-to-head trial for patients with atopic dermatitis.
Boehringer Ingelheim partners with Cinga to push their Humira biosimilar.
Merck's Keytruda has helped the company take a slim lead over others in a survey conducted to find out oncologists perceptions of pharma manufacturers in the oncology space.
%402x.svg){kind=icon}
.png)
%402x.svg){kind=icon}
